Selling a B2B SaaS product to pharmaceutical companies is a different game from selling software to health providers — stricter, slower, and less forgiving of the usual outbound reflexes. If your buyers are pharma companies (or biotechs and CROs), or you're a healthtech founder who assumed pharma was "just healthcare," this is where the rules change. Across practitioners comparing notes — including founders selling exactly this kind of platform into pharma — the same hard truths and the same workarounds keep coming up. Here's the playbook, including where B2B pharma marketing actually helps and where it doesn't. (Selling to clinics, pharmacies and practices is a separate, warmer motion — that's B2B outreach for healthtech.)
Why pharma is uniquely hard
Get the terrain straight, because it explains everything that follows.
- Regulated buyers won't risk a startup. In critical, regulated environments, large pharma simply won't touch a small, unproven vendor. The more important your product, the harder it gets — they'll spend millions with an established player before taking a risk on you.
- Incumbents are baked in. Big pharma runs on platforms like Veeva and Cortellis, and local branches follow a global standard. You're not replacing a spreadsheet — you're arguing with a company-wide practice.
- Becoming an approved supplier is itself a process. Procurement, security, compliance and legal all gate the deal long before anyone signs.
- Email alone won't move them. As one operator put it, they won't react unless they're in great pain, desperate for a solution — so personal contact and credibility matter more than any sequence. (It's the same reason generic cold email gets ignored everywhere, amplified.)
Pointing a normal outbound motion at pharma and expecting replies will disappoint you. The work is credibility and access, not send volume.
1 · The user is not the buyer
A trap that catches a lot of pharma-focused startups: the people using and enjoying your platform are staff, not management. They'll tell you it's helpful — and still have no authority to pay for it. Worse, the workload you save them may not be a big enough pain to move a budget on its own. Getting a handful of active users from one or two companies feels like traction, but if none of them can buy, it isn't.
Count buyers, not users. Enthusiastic staff who can't authorise spend are validation of the product, not of the pipeline.
2 · Sell a consequence, not convenience
If "saves time" won't move a budget, what will? Map the process your product touches — before and after, and everything it connects to — and ask what happens if it breaks. Compliance risk? A failed audit? Missed regulatory updates leading to fines? Those answers reveal the real pain, the one management actually loses sleep over. Reframe your whole pitch from convenience to consequence: not "we make this faster," but "we remove this risk you're accountable for."
Find the expensive failure your product prevents — audit, fine, compliance breach — and lead with that. Time saved is a footnote; risk removed is a budget line.
3 · Cold outreach won't do it — get an insider
Because the whole market runs on trust and risk, the way in is credibility you borrow from someone who already has it. The practitioners who break into pharma do it through access, not cold volume:
- Partner with an insider — someone who knows the field from the inside and can open doors and vouch for you. Without one, you can spend years posting, emailing and meeting with nothing to show.
- Work with established firms — an existing pharma company or a consultancy that already supplies your targets. Selling through a trusted supplier beats selling around them.
- Bring in pharma-specialised investors — a VC who knows the space can introduce you to the right companies and lend the credibility a young vendor lacks.
- Show up at industry events — where regulated buyers actually assess new vendors face to face.
It's the same principle as the wider channel breakdown — map where your buyers actually build trust, then concentrate there — just weighted almost entirely toward warm access rather than reach.
Your first real pipeline in pharma probably comes from one warm insider, not a thousand cold emails. The same is true of most gated verticals — we've written the equivalent playbook for legaltech, where the trust problem looks almost identical. Invest in access and endorsement before volume.
4 · Give them a real reason to change
Pharma buyers almost always have an incumbent, so "we're better" isn't a reason to move. Remember what you're actually asking for: not their money, but their time and their internal reputation, to champion a switch that could go wrong on their watch. So you have to bring the reason — a compelling event or consequence that makes doing nothing the risky choice. Do that groundwork before you reach out; a generic "here's what we do" gets ignored, while a specific, consequential trigger earns a conversation.
You're not asking for their budget — you're asking them to put their own reputation on the line for you. Bring a reason big enough to be worth that.
Identify the specific reason-to-change per account before the first touch. In pharma, the reason is the outreach — everything else is packaging.
5 · Land where you can grow with the customer
Fighting incumbents head-on for a big pharma's core platform is a losing opening move. A smarter entry: niche into a specific stage or need where you can win, then grow alongside the customer. One life-science operator's version — become the compliance-and-legal layer that spans drug discovery through to manufacturing (GLP, GCP, GMP) — opens up biotechs at any stage and CROs, not just big pharma. Acquire customers early, when they're IND-enabling and just starting out, support them through clinical trials, and stay through to manufacturing. You grow with them instead of trying to rip out an entrenched player on day one. And think about distribution from the very start — how you'll reach these buyers is a design question, not an afterthought.
Pick an entry point you can actually win — an early stage, a narrow need, a smaller buyer — and expand from inside the account. Beat the incumbent by outgrowing it, not out-pitching it.
6 · Precision and patience
Pharma pipelines are low-volume and high-value, and they move at the speed of trust and contract cycles, not urgency. A handful of qualified, well-fit conversations a month can be a healthy engine when each account is large and sticky. Expect long, multi-threaded cycles; the first meeting's job is to earn the second, and every follow-up has to add something new. Reps who bring manufactured urgency lose; reps who stay relevant and let credibility compound win — and keep the account for years. The same signal-and-firmographic timing that helps everywhere applies here too (see the outreach tools breakdown) — it just sits on top of relationships, not instead of them.
This sale moves at the speed of trust and contract cycles, not urgency. Your job on the first call isn't to close — it's to earn the second conversation.
7 · Where marketing fits
If cold volume doesn't open doors, what is marketing even for here? Not lead capture. In this market B2B pharma marketing has one job: make you look like a safe supplier before anyone talks to you. A regulated buyer who is about to champion an unknown vendor will look you up first, and what they find either supports the risk they're taking or quietly ends it.
So the assets that earn their keep are the boring ones. A written-down compliance and security posture. Named customers, or at least named categories of customer. A case study a champion can forward to procurement without having to explain it. Talks and presence at the events your buyers already attend. None of that generates a lead on its own — it removes reasons to say no from the person who is already interested.
It's also worth separating pharma lead generation from lead generation everywhere else in B2B, because the usual metrics mislead here. Volume targets don't apply: a month with six qualified accounts and zero form fills can be a good month. Count accounts where you have real access and a real reason to change — that's the number that predicts revenue in this vertical.
The same shape holds across B2B life science marketing more broadly — biotechs, CROs, device and diagnostics companies. The trust structure is identical, but the gates are lower at the small end, which is exactly why landing early (section 5) works better than aiming at big pharma first.
Marketing's job in pharma is de-risking you, not filling a funnel. Publish the things a cautious buyer checks before they vouch for you internally — then judge the work by qualified accounts, not lead volume.
The takeaway
Selling software to pharmaceutical companies rewards patience, credibility and precision. Count buyers, not users. Sell the consequence you remove, not the time you save. Get in through an insider or partner rather than cold volume, bring a reason big enough to justify the risk you're asking someone to take, and land where you can grow with the customer instead of fighting the incumbent on day one. It's slow — but the accounts are enormous, sticky, and barely contested once you're trusted.
Running that motion — the research, the warm access, the compliance-aware messaging and the long, patient nurture — across a regulated market is a lot to hold. It's exactly the kind of pipeline we build and run for clients. And if your buyers are clinics and pharmacies rather than pharma companies, start with the healthtech playbook instead.